Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
294,683,714
-
Number of holders
-
125
-
Total 13F shares, excl. options
-
100,425,667
-
Shares change
-
+14,050,163
-
Total reported value, excl. options
-
$67,257,419
-
Value change
-
+$9,590,265
-
Put/Call ratio
-
185%
-
Number of buys
-
46
-
Number of sells
-
-66
-
Price
-
$0.6702
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q1 2024
146 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q1 2024.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 125 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 100,425,667 shares
of 294,683,714 outstanding shares and own 34% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS LP (20,132,324 shares), ARMISTICE CAPITAL, LLC (16,958,477 shares), BlackRock Inc. (13,277,637 shares), VANGUARD GROUP INC (12,200,368 shares), ACADIAN ASSET MANAGEMENT LLC (4,943,260 shares), GEODE CAPITAL MANAGEMENT, LLC (3,363,791 shares), D. E. Shaw & Co., Inc. (3,067,435 shares), STATE STREET CORP (2,751,804 shares), RENAISSANCE TECHNOLOGIES LLC (2,597,977 shares), and TWO SIGMA ADVISERS, LP (1,428,255 shares).
This table shows the top 125 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.